Experience of dolutegravir in HIV-infected treatment-naive patients from a tertiary care University Hospital in Ireland:

SAGE Open Medicine

SarmadWaqas¹ 

关键词: Pharmacoepidemiology/drug safety;    dolutegravir;    HIV;    viral load;    naive;    integrase inhibitor;    tolerability;   

DOI  :  10.1177/2050312116675813

学科分类：医学（综合）

来源: Sage Journals

【 摘 要 】

Objective:Dolutegravir, an HIV integrase inhibitor, is a relatively new treatment option. To assess the tolerability, side effects, and time to viral decline to non-detectable in patients newly started on dolutegravir.Methods:Retrospective health care record of 61 consecutive HIV treatment-naive patients started on dolutegravir was reviewed and analysed on SPSS.Results:The mean initial viral load was 160826.05 copies/mL (range, 79–1,126,617 copies/mL). HIV viral load became non-detectable in 63.9% of patients on dolutegravir within 3 months. In all, 60.7% of patients reported no side effects on dolutegravir; 98.4% of the patients claimed full compliance to their antiretrovirals.Conclusion:Dolutegravir was found to be efficacious and well tolerated in HIV-infected treatment-naive patients.

【 授权许可】

CC BY